Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 30-Sep-24 4:15 PM View:  | Watson David O. General Counsel | Apellis Pharmaceuticals, Inc. (APLS) | 27-Sep-24 | Gift | 10,569 | -- | -- | (5%) 208.43K to 197.86K | |
| 30-Sep-24 4:15 PM View: | Watson David O. General Counsel | Apellis Pharmaceuticals, Inc. (APLS) | 27-Sep-24 | Gift | 10,569 | -- | -- | 5% 197.86K to 208.43K | |
| 24-Sep-24 4:20 PM View: | Dunlop A. Sinclair Director | Apellis Pharmaceuticals, Inc. (APLS) | 23-Sep-24 | Option Exercise | 4,600 | $13.19 | $60,674.00 | 2% 247.53K to 252.13K | |
| 17-Sep-24 4:08 PM View: | Chopas James George VP/Chief Accounting Officer | Apellis Pharmaceuticals, Inc. (APLS) | 16-Sep-24 | Sale | 192 | $36.21 | $6,951.55 | (< 1%) 38.33K to 38.14K | |
| 17-Sep-24 5:21 PM View: | Dunlop A. Sinclair Director | Apellis Pharmaceuticals, Inc. (APLS) | 16-Sep-24 | Sale (Planned) | 37,000 | $36.23 | $1,340,600.00 | (13%) 284.53K to 247.53K | |
| 13-Aug-24 4:13 PM View: | Delong Mark Jeffrey Chief Business & Strat Officer | Apellis Pharmaceuticals, Inc. (APLS) | 12-Aug-24 | Option Exercise | 5,201 | $13.85 | $72,033.90 | 9% 55.19K to 60.4K | |
| 01-Jul-24 4:02 PM View: | Dunlop A. Sinclair Director | Apellis Pharmaceuticals, Inc. (APLS) | 28-Jun-24 | Option Exercise | 900 | $13.19 | $11,871.00 | < 1% 302.37K to 303.27K | |
| 21-Jun-24 7:34 PM View: | Dunlop A. Sinclair Director | Apellis Pharmaceuticals, Inc. (APLS) | 21-Jun-24 | Market Sale (Planned) | 37,000 | $39.24 | $1,451,840.00 | (11%) 339.37K to 302.37K | (13%) |
| 21-May-24 4:03 PM View: | Deschatelets Pascal Chief Scientific Officer | Apellis Pharmaceuticals, Inc. (APLS) | 20-May-24 | Option Exercise | 24,500 | $3.76 | $92,120.00 | 2% 1.12M to 1.14M | |
| 09-May-24 5:15 PM View: | Deschatelets Pascal Chief Scientific Officer | Apellis Pharmaceuticals, Inc. (APLS) | 08-May-24 | Option Exercise | 78,907 | $4.31 | $340,089.00 | 7% 1.12M to 1.19M | |
| 09-May-24 5:15 PM View: | Deschatelets Pascal Chief Scientific Officer | Apellis Pharmaceuticals, Inc. (APLS) | 08-May-24 | Planned Option Sale | 78,907 | $42.35 | $3,341,850.00 | (7%) 1.19M to 1.12M | |
| 19-Apr-24 7:27 PM View: | Sullivan Timothy Eugene Chief Financial Officer | Apellis Pharmaceuticals, Inc. (APLS) | 18-Apr-24 | Gift | 14,164 | -- | -- | (9%) 163.73K to 149.57K | |
| 19-Apr-24 7:27 PM View: | Sullivan Timothy Eugene Chief Financial Officer | Apellis Pharmaceuticals, Inc. (APLS) | 18-Apr-24 | Gift | 14,164 | -- | -- | 9% 149.57K to 163.73K | |
| 15-Apr-24 4:09 PM View: | Dunlop A. Sinclair Director | Apellis Pharmaceuticals, Inc. (APLS) | 12-Apr-24 | Option Exercise | 1,500 | $13.19 | $19,785.00 | < 1% 337.87K to 339.37K | |
| 09-Apr-24 4:25 PM View: | Deschatelets Pascal Chief Scientific Officer | Apellis Pharmaceuticals, Inc. (APLS) | 08-Apr-24 | Option Exercise | 69,107 | $3.76 | $259,842.00 | 6% 1.12M to 1.19M | |
| 09-Apr-24 4:25 PM View: | Deschatelets Pascal Chief Scientific Officer | Apellis Pharmaceuticals, Inc. (APLS) | 08-Apr-24 | Planned Option Sale | 69,107 | $54.17 | $3,743,610.00 | (6%) 1.19M to 1.12M | |
| 02-Apr-24 4:06 PM View: | Sullivan Timothy Eugene Chief Financial Officer | Apellis Pharmaceuticals, Inc. (APLS) | 01-Apr-24 | Option Exercise | 4,000 | $10.03 | $40,120.00 | 3% 149.57K to 153.57K | |
| 02-Apr-24 4:06 PM View: | Sullivan Timothy Eugene Chief Financial Officer | Apellis Pharmaceuticals, Inc. (APLS) | 01-Apr-24 | Planned Option Sale | 4,000 | $58.66 | $234,640.00 | (3%) 153.57K to 149.57K | |
| 20-Mar-24 5:18 PM View: | Dunlop A. Sinclair Director | Apellis Pharmaceuticals, Inc. (APLS) | 19-Mar-24 | Private Sale | 18,681 | $57.18 | $1,068,160.00 | (5%) 356.55K to 337.87K | |
| 19-Mar-24 4:03 PM View: | Delong Mark Jeffrey Chief Business & Strat Officer | Apellis Pharmaceuticals, Inc. (APLS) | 18-Mar-24 | Private Sale | 9,913 | $56.90 | $564,050.00 | (15%) 64.61K to 54.69K | |
| 18-Mar-24 4:19 PM View: | Chopas James George VP/Chief Accounting Officer | Apellis Pharmaceuticals, Inc. (APLS) | 15-Mar-24 | Private Sale | 184 | $56.46 | $10,388.80 | (< 1%) 39.07K to 38.88K | |
| 14-Mar-24 4:17 PM View: | Nicholson Nur Chief Technical Officer | Apellis Pharmaceuticals, Inc. (APLS) | 13-Mar-24 | Private Sale | 11,220 | $57.56 | $645,838.00 | (17%) 67.51K to 56.29K | |
| 11-Mar-24 4:08 PM View: | Deschatelets Pascal Chief Scientific Officer | Apellis Pharmaceuticals, Inc. (APLS) | 08-Mar-24 | Planned Option Sale | 69,107 | $62.19 | $4,297,550.00 | (6%) 1.19M to 1.12M | |
| 11-Mar-24 4:08 PM View: | Deschatelets Pascal Chief Scientific Officer | Apellis Pharmaceuticals, Inc. (APLS) | 08-Mar-24 | Option Exercise | 69,107 | $3.67 | $253,623.00 | 6% 1.12M to 1.19M | |
| 08-Mar-24 7:45 AM View: | Watson David O. General Counsel | Apellis Pharmaceuticals, Inc. (APLS) | 06-Mar-24 | Option Exercise | 3,762 | $13.85 | $52,103.70 | 2% 194.09K to 197.86K | |
| 05-Mar-24 4:07 PM View: | Francois Cedric Chief Executive Officer Director | Apellis Pharmaceuticals, Inc. (APLS) | 01-Mar-24 | Option Exercise | 250,000 | $4.20 | $1,050,000.00 | 12% 2.04M to 2.29M | |
| 05-Mar-24 4:07 PM View: | Francois Cedric Chief Executive Officer Director | Apellis Pharmaceuticals, Inc. (APLS) | 01-Mar-24 | Option Sale | 250,000 | $64.11 | $16,028,700.00 | (11%) 2.29M to 2.04M | |
| 05-Mar-24 4:04 PM View: | Sullivan Timothy Eugene Chief Financial Officer | Apellis Pharmaceuticals, Inc. (APLS) | 01-Mar-24 | Planned Option Sale | 6,000 | $63.22 | $379,340.00 | (4%) 155.57K to 149.57K | |
| 05-Mar-24 4:04 PM View: | Sullivan Timothy Eugene Chief Financial Officer | Apellis Pharmaceuticals, Inc. (APLS) | 01-Mar-24 | Option Exercise | 6,000 | $10.03 | $60,180.00 | 4% 149.57K to 155.57K | |
| 13-Feb-24 4:38 PM View: | Delong Mark Jeffrey Chief Business & Strat Officer | Apellis Pharmaceuticals, Inc. (APLS) | 12-Feb-24 | Private Sale | 597 | $67.77 | $40,456.80 | (< 1%) 65.2K to 64.61K | |
| 13-Feb-24 5:05 PM View: | Townsend Adam J. Chief Commercial Officer | Apellis Pharmaceuticals, Inc. (APLS) | 12-Feb-24 | Private Sale | 1,148 | $67.77 | $77,796.40 | (1%) 93.6K to 92.45K | |
| 13-Feb-24 5:06 PM View: | Watson David O. General Counsel | Apellis Pharmaceuticals, Inc. (APLS) | 12-Feb-24 | Private Sale | 781 | $67.77 | $52,925.90 | (< 1%) 194.88K to 194.09K | |
| 13-Feb-24 4:49 PM View: | Francois Cedric Chief Executive Officer Director | Apellis Pharmaceuticals, Inc. (APLS) | 12-Feb-24 | Private Sale | 3,962 | $67.77 | $268,492.00 | (< 1%) 2.04M to 2.04M | |
| 13-Feb-24 4:59 PM View: | Sullivan Timothy Eugene Chief Financial Officer | Apellis Pharmaceuticals, Inc. (APLS) | 12-Feb-24 | Private Sale | 1,431 | $67.77 | $96,974.40 | (< 1%) 151.0K to 149.57K | |
| 13-Feb-24 4:43 PM View: | Deschatelets Pascal Chief Scientific Officer | Apellis Pharmaceuticals, Inc. (APLS) | 12-Feb-24 | Private Sale | 1,148 | $67.77 | $77,796.40 | (< 1%) 1.12M to 1.12M | |
| 31-Jan-24 4:28 PM View: | Lewis Karen Chief People Officer | Apellis Pharmaceuticals, Inc. (APLS) | 30-Jan-24 | Sale (Planned) | 883 | $65.53 | $57,863.00 | (2%) 47.27K to 46.39K | |
| 31-Jan-24 4:23 PM View: | Eisele Jeffrey Chief Development Officer | Apellis Pharmaceuticals, Inc. (APLS) | 30-Jan-24 | Sale (Planned) | 971 | $65.53 | $63,629.60 | (2%) 58.18K to 57.21K | |
| 31-Jan-24 4:18 PM View: | Delong Mark Jeffrey Chief Business & Strat Officer | Apellis Pharmaceuticals, Inc. (APLS) | 29-Jan-24 | Private Sale | 367 | $64.14 | $23,538.70 | (< 1%) 65.57K to 65.2K | |
| 31-Jan-24 4:36 PM View: | Townsend Adam J. Chief Commercial Officer | Apellis Pharmaceuticals, Inc. (APLS) | 29-Jan-24 | Private Sale | 906 | $64.14 | $58,109.20 | (< 1%) 94.51K to 93.6K | |
| 31-Jan-24 4:38 PM View: | Watson David O. General Counsel | Apellis Pharmaceuticals, Inc. (APLS) | 29-Jan-24 | Private Sale | 906 | $64.14 | $58,109.20 | (< 1%) 195.78K to 194.88K | |
| 31-Jan-24 4:26 PM View: | Francois Cedric Chief Executive Officer Director | Apellis Pharmaceuticals, Inc. (APLS) | 29-Jan-24 | Private Sale | 2,843 | $64.14 | $182,345.00 | (< 1%) 2.04M to 2.04M | |
| 31-Jan-24 4:31 PM View: | Nicholson Nur Chief Technical Officer | Apellis Pharmaceuticals, Inc. (APLS) | 29-Jan-24 | Private Sale | 835 | $64.14 | $53,555.40 | (1%) 68.34K to 67.51K | |
| 31-Jan-24 4:34 PM View: | Sullivan Timothy Eugene Chief Financial Officer | Apellis Pharmaceuticals, Inc. (APLS) | 29-Jan-24 | Private Sale | 906 | $64.14 | $58,109.20 | (< 1%) 151.91K to 151.0K | |
| 31-Jan-24 4:21 PM View: | Deschatelets Pascal Chief Scientific Officer | Apellis Pharmaceuticals, Inc. (APLS) | 29-Jan-24 | Private Sale | 874 | $64.14 | $56,056.80 | (< 1%) 1.12M to 1.12M | |
| 31-Jan-24 4:28 PM View: | Lewis Karen Chief People Officer | Apellis Pharmaceuticals, Inc. (APLS) | 29-Jan-24 | Private Sale | 367 | $64.14 | $23,538.70 | (< 1%) 47.64K to 47.27K | |
| 31-Jan-24 4:23 PM View: | Eisele Jeffrey Chief Development Officer | Apellis Pharmaceuticals, Inc. (APLS) | 29-Jan-24 | Private Sale | 279 | $64.14 | $17,894.60 | (< 1%) 58.46K to 58.18K | |
| 24-Jan-24 4:06 PM View: | Lewis Karen Chief People Officer | Apellis Pharmaceuticals, Inc. (APLS) | 23-Jan-24 | Private Sale (Planned) | 4,286 | $63.69 | $272,975.00 | (8%) 51.92K to 47.64K | |
| 24-Jan-24 4:03 PM View: | Eisele Jeffrey Chief Development Officer | Apellis Pharmaceuticals, Inc. (APLS) | 23-Jan-24 | Private Sale (Planned) | 7,378 | $63.69 | $469,905.00 | (11%) 65.84K to 58.46K | |
| 23-Jan-24 7:28 PM View: | Francois Cedric Chief Executive Officer Director | Apellis Pharmaceuticals, Inc. (APLS) | 22-Jan-24 | Private Sale | 13,431 | $65.00 | $872,961.00 | (< 1%) 2.06M to 2.04M | |
| 23-Jan-24 6:11 PM View: | Nicholson Nur Chief Technical Officer | Apellis Pharmaceuticals, Inc. (APLS) | 22-Jan-24 | Private Sale | 2,593 | $65.00 | $168,535.00 | (4%) 70.94K to 68.34K |
